In this article, we will look at the 8 Cheap Large Cap Stocks to Buy Now.
Cheap large-cap stocks are getting more attention as investors are looking past the market’s most crowded winners and are now putting more weight on the current entry points. This matters in a market where broad indices still look expensive even as plenty of individual large-cap names have already reset. Large caps do not usually get framed as bargain territory, but that changes when sentiment cools, leadership broadens, and investors begin separating the index from the stocks inside it.
J.P. Morgan Asset Management says the “value factor remains attractive globally” and that the “quality factor is also inexpensive in the U.S.” Fidelity makes a similar point from the stock-picking side, saying investors can use volatility to “buy quality stocks” at “discounted prices.” At the same time, market pullbacks can create chances to pick up names at “temporarily marked-down prices.” Putnam Investments adds that while the S&P 500 is “more expensive than average,” “many in this cohort are trading in line with or cheaper than their historical averages.” The headline market may not look cheap, but parts of the large-cap universe still do.
Against this backdrop, large-cap stocks with lower valuations become harder to ignore. That brings us to the 8 Cheap Large Cap Stocks to Buy Now.
Our Methodology
We used the Finviz screener to identify large-cap stocks that are trading below a forward P/E of 15 and limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Toyota Motor Corporation (NYSE:TM)
On April 2, 2026, Erste Group downgraded Toyota Motor Corporation (NYSE:TM) to Hold from Buy. Erste Group said Toyota continues to deliver higher profitability than peers, with return on equity and operating margins above sector averages, supported by strong global positioning and demand for hybrid vehicles. However, the firm noted that higher energy prices and weaker consumer confidence in key markets could limit revenue growth despite planned expansion in hybrid production and sales.
On April 1, 2026, Toyota Motor Corporation (NYSE:TM) reported March U.S. sales of 211,617 units, down 8.5%.
Last month, Toyota marked 40 years at its Kentucky plant and announced a $1 billion investment across its Kentucky and Indiana operations as part of a broader plan to invest up to $10 billion in U.S. plants over five years. The investment includes $800 million in Kentucky to support electrification and increase capacity for Camry and RAV4 production, and $200 million in Indiana to expand Grand Highlander capacity alongside Sienna and Lexus TX production.
Toyota Motor Corporation (NYSE:TM) manufactures and sells vehicles and automotive products globally.
7. Pfizer Inc. (NYSE:PFE)
On April 9, 2026, BofA lowered the price target on Pfizer Inc. (NYSE:PFE) to $26 from $27 and maintained a Neutral rating. BofA said the change reflects updates made as part of its Q1 preview across large-cap pharma and small-to-mid cap biopharma coverage.
On April 1, 2026, a Belgian court ordered Poland and Romania to accept and pay for EUR 1.9B worth of Covid-19 vaccines from Pfizer, rejecting arguments for non-compliance with a European Commission supply contract. Poland is required to take EUR 1.3B worth of doses and Romania EUR 600M after both had refused delivery citing pandemic developments and other concerns.
On March 24, 2026, Guggenheim raised its price target on Pfizer to $36 from $35 and maintained a Buy rating, citing upcoming Phase 3 data for mevrometostat expected in the second half of 2026 and noting potential upside versus downside scenarios tied to the trial outcome.
On March 23, 2026, Pfizer and Valneva reported Phase 3 VALOR trial results for their Lyme disease vaccine candidate, showing efficacy of 73.2% and 74.8% in two analyses, while noting the first pre-specified statistical criterion was not met due to fewer cases, but indicating plans for regulatory submissions.
Pfizer Inc. (NYSE:PFE) develops and commercializes biopharmaceutical products globally.
Hedge Fund Resource Center